Modelled DT Structure
Method: homology modeling
Template PDB: 2XQ2_A
Identity: 32.765%
Minimized Score: -1079.765 kcal/mol
Detail: Structure Info
Drug Transporter (DT) Information
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0420 | ||||
| Gene Name | SLC5A11 | ||||
| Protein Name | Sodium/myo-inositol cotransporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
|
||||
| Synonyms | KST1; Na(+)/myo-inositol cotransporter 2; RKST1; SGLT6; SLC5A11; SLGTX; SMIT2; Sodium-dependent glucose cotransporter; Sodium/glucose cotransporter KST1; Sodium/myo-inositol transporter 2; Solute carrier family 5 member 11 | ||||
| DT Family | Solute:Sodium Symporter (SSS) Family ; | ||||
| Function | This transporter involved in the sodium-dependent cotransport of myo-inositol (MI) with a Na(+):MI stoichiometry of 2:1. Exclusively responsible for apical MI transport and absorption in intestine. Also can transport D-chiro-inositol (DCI) but not L-fructose. Exhibits stereospecific cotransport of both D-glucose and D-xylose. May play a role in the regulation of MI concentration in serum, involving reabsorption in at least the proximal tubule of the kidney. | ||||
| Endogenous Substrate(s) | Na+ | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
MYO-inositol
|
Phase 4 | Drug Info | Polycystic ovary syndrome | 5A80.1 | [1] |
| References | |||||
| 1 | The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.